

Zagreb, travanj, 2013


# SEKCIJA ZA TRANSLACIJSKU MEDICINU

Hrvatsko ortopedsko društvo




*doc.dr.sc. Alan Ivković*

# TRI STOLJEĆA ORTOPEDIJE




# POGLED U ORTOPEDSKI RETROVIZOR



'60



'80



'90




'00



# IZAZOVI 21. STOLJEĆA

- Proteomika, genomika, metabolomika
- Tkivni inženjering
- Regenerativna medicina
- Stanična terapija
- Genska terapija
- Znanost o materijalima
- Transgenični animalni modeli
- Strukturna biologija
- Slikovne metode
- .....



# TRANSLACIJSKA MEDICINA

KLINIKA



BAZIČNA  
ZNANOST



TRANSLACIJSKA  
MEDICINA



# TRANSLACIJSKA ISTRAŽIVANJA

The NEW ENGLAND JOURNAL of MEDICINE

## SOUNDING BOARD

### Translational and Clinical Science — Time for a New Vision

Elias A. Zerhouni, M.D.

It is the responsibility of those of us involved in today's biomedical research enterprise to translate the remarkable scientific innovations we are witnessing into health gains for the nation. In order to address this imperative, we at the National Institutes of Health (NIH) asked ourselves: What novel approaches can be developed that have the potential to be truly transforming for human health? To help crystallize these ideas and develop tangible strategies to advance our efforts, three years ago the NIH initiated a series of consultations with the re-

paramount among the NIH's immediate responsibilities. This led us to formulate the third Roadmap theme, "Re-engineering the Clinical Research Enterprise."

Translational and clinical research are core components of a full-spectrum biomedical research enterprise. Yet, these critical arenas of research are hampered by increases in costs and complexity, a dearth of information systems, and increases in the regulatory burden. An explosion in clinical-service demands and reduced financial margins have sharp-

# HRVATSKA ORTOPEDIJA I TRANSLACIJSKA MEDICINA

## BIO-COMET

**Title:** Bioreactor-based, clinically oriented manufacturing of engineered tissues

**Research area:** HEALTH.2011.1.4-2 Tools, technologies and devices for application in regenerative medicine

**Project start date:** [2011-12-01]

## OSTEOGROW

**Title:** Novel Bone Morphogenetic Protein-6 Biocompatible Carrier Device for Bone Regeneration

**Research area:** HEALTH.2011.1.4-1 Regenerative medicine clinical trials

**Project start date:** [2012-01-01]

## MAGISTER

**Title:** Magnetic scaffolds for in vivo tissue engineering


**Research area:** NMP-2007-2.3-1 Highly porous bioactive scaffolds favouring angiogenesis for tissue engineering

**Project start date:** [2008-12-01]





# HORIZON 2014-2020



80 mlrd Eura



EFORT Head Office  
ZA La Pièce 2  
1180 Rolle, Switzerland  
Tel +41 21 343 44 00  
Fax +41 21 343 44 11  
office@efort.org  
www.efort.org



To: Members of National Societies and Specialty Societies

RE: EFORT's actions towards the future EU Research Framework Program: Horizon 2020

Dear colleagues

Last October, EFORT, in collaboration with EULAR (European League against Rheumatism), organised an EU workshop support the prioritization of research in the field of Musculoskeletal Diseases (MSDs) for the next decade. This was aimed at including formally research in the musculoskeletal field into the Horizon 2020 programme.

Following this event, on November 28<sup>th</sup>, the European Parliament voted in Committee (ITRE) an amended Horizon 2020 Proposal inclusive of MSDs. For EFORT and for the orthopaedic research community this ITRE vote is excellent news and confirms the recognition of the burden of musculoskeletal conditions throughout the European Union. Once the EU multi-financial framework is adopted and the text reaches its final agreement with the Council of Ministers, the research calls under Horizon 2020 will include musculoskeletal conditions.

Recently the European Commission has launched a call asking experts from all fields to participate in shaping the agenda of Horizon 2020 by entering advisory groups. The groups will encourage dialogue between all levels of government, civil society and business from all EU Member States, and by this influence the direction of EU research and innovation funding from now until 2020.

The expert advisory groups will start their work during spring of this year to provide advice in time for the first Horizon 2020 calls, which are expected to be launched by the end of 2013.

This call represents a unique opportunity to influence Horizon 2020 and to communicate on the added value of Research projects in MSDs for all EU citizens. We therefore encourage you to participate and to communicate this opportunity to fellow members of your National or Specialty Societies. All information on Horizon 2020 are to be found on the official website under <http://ec.europa.eu/research/horizon2020>.

Best regards

**Prof Dr Wolfhart Puhl**  
EFORT Past President  
Chairman European Affairs

**Prof Dr Pierre Hoffmeyer**  
EFORT President


<b>PRESIDENT</b> Prof. Dr. Pierre Hoffmeyer pierre.hoffmeyer@efort.org	<b>VICE PRESIDENT</b> Dr. Manuel Cassiano Neves manuel.cassiano.neves@efort.org	<b>SECRETARY GENERAL</b> Ass. Prof. Dr. Per Kjærsgaard-Andersen per.kjaersgaard-andersen@efort.org	<b>PAST PRESIDENT</b> Prof. Dr. Mikko Saareldi mikko.saareldi@efort.org
<b>TREASURER</b> Mr. Stephen R. Cannon stephen.cannon@efort.org	<b>MEMBER</b> Prof. Dr. Enric Cáceres Patou enric.caceres@efort.org	<b>MEMBER</b> Dr. George Macheras george.macheras@efort.org	<b>MEMBER</b> Prof. Dr. Philippe Neyret philippe.neyret@efort.org

# SEKCIJA ZA TRANSLACIJSKU MEDICINU HOD-a

- Promicanje primjene translacijskih principa u bazičnoj i kliničkoj ortopediji organiziranjem stručnih i znanstvenih sastanaka, seminara, kongresa, predavanja i tečajeva
- Suradnja s društvima i sekcijama HLZ-a na područjima od zajedničkog interesa
- Suradnja sa srodnim stručnim i znanstvenim društvima drugih zemalja
- Predlaganje znanstvenih projekata
- Baza mentora, tema doktorata...



Found in  
**TRANSLATION**



**HVALA**